Type III Prostatitis
Conditions
Interventions
Treatment group:Oral administration of 1 placebo capsule once daily before bedtime
2 sachets of Qianlie Tongluo formula-free granules twice daily, infused with 200 mL warm boiled water
Control group::Oral administration of 1 Tamsulosin Hydrochloride Capsule once daily before bedtime
2 sachets of placebo herbal granules twice daily, infused with 200 mL warm boiled water
Sponsors
Dongzhimen Hospital, Beijing University of Chinese Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: (1) Male patients meeting the Western medicine diagnostic criteria for type III prostatitis; (2) NIH-CPSI score > 10 points; (3) Patients conforming to the syndrome differentiation standard of damp-heat stagnation and blood stasis syndrome; (4) Patients with relevant symptoms consistent with diagnostic criteria lasting for more than 3 months; (5) Aged from 18 to 50 years old (inclusive); (6) No antibiotics or treatments for chronic prostatitis administered within 2 weeks before enrollment; (7) No other medications taken by patients within two weeks prior to enrollment; (8) Patients fully informed of the trial conditions and voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients complicated with prostatic tumors, neurogenic bladder dysfunction, urethral malformation or stricture, and severe neurosis. (2) Patients with urinary tract infection or urethritis. (3) For patients presenting mainly with local pain, other diseases involving lower abdomen, perineum, lumbosacral region and other parts shall be excluded, such as ureteral or vesical calculi, inguinal hernia, pubic osteitis, varicocele, epididymitis, colorectal diseases, lumbodorsal fasciitis, etc. (4) Patients complicated with severe primary diseases of cardiovascular and cerebrovascular systems, liver, kidney and hematopoietic system. (5) Subjects participating in other clinical drug trials concurrently or taking drugs with similar therapeutic effects to the trial medication. (6) Patients who use Chinese and Western medicines, health products, or herbal decoctions containing prescribed medicinal slices with therapeutic effects on this disease during the trial period. (7) Patients with fertility requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| National Institutes of Health Chronic Prostatitis Symptom Index; | — |
Secondary
| Measure | Time frame |
|---|---|
| International Index of Erectile Function-5;Generalized Anxiety Disorder-7;Patient Health Questionnaire-9;Traditional Chinese Medicine Syndrome Score Scale;Routine semen analysis; | — |
Countries
China
Contacts
Public ContactLi Haisong
Dongzhimen Hospital, Beijing University of Chinese Medicine
Outcome results
None listed